目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T69011 | |||
Lobeglitazone, also known as CKD-501, is an antidiabetic drug in the thiazolidinedione class of drugs. As an agonist for both PPARα and PPARγ, it works as an insulin sensitizer by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. | |||
T70367 | |||
SNU-BP is an agonist of PPAR-gamma, inhibiting lipopolysaccharide (LPS)-induced NO production and pro-inflammatory cytokines. SNU-BP potentiates interleukin-4-induced arginase-1 expression, and promotes microglial polarization toward an M2 anti-inflammatory phenotype. | |||
TMIH-0516 | |||
Saroglitazar-d4 是 Saroglitazar 的氘代化合物。Saroglitazar 的 CAS 号为 495399-09-2。Saroglitazar 是 PPAR 的激动剂,对 PPARα 和 PPARγ 的 EC50 值为 0.65 pM 和 3 nM。 | |||
T70886 | |||
PT-S58 is a PPAR β/δ full antagonist, and a derivative of GSK0660. PT-S58 has a three-fold higher affinity for the receptor than GSK0660 and is a potent inhibitor of agonist-induced target gene expression. PT-S58 are effective on PPRE-independent functions of PPARβ/δ. Unlike GSK0660, PT-S58 blocks the recruitment co-repressor molecules such as SMRT. | |||
TMIH-0517 | |||
Saroglitazar oxide-d4 是 Saroglitazar oxide 的氘代化合物。Saroglitazar oxide 的 CAS 号为 495399-09-2。Saroglitazar 是 PPAR 的激动剂,对 PPARα 和 PPARγ 的 EC50 值为 0.65 pM 和 3 nM。 | |||
TN3655 | ERK TNF ROS Akt PI3K PKC PPAR | ||
Cimiside E has anti-inflammatory activity, it selectively inhibits TNF-α-induced expression of VCAM-1 at least by upregulation of PPAR-γ, and signals for ERK1/2, PI3K, and PKC are involved in this effect.Cimiside E may be an effective chemopreventive agen | |||
T60432 | |||
NAAA-IN-3 (Compound 17a) 是一种有效的、选择性的 NAAA 抑制剂,IC50为 50 nM。NAAA 是一种半胱氨酸酰胺酶,它优先水解内源性生物脂棕榈酰乙醇酰胺 (PEA) 和油酰乙醇酰胺 (OEA)。PEA 是核过氧化物酶体增殖物激活受体-α (PPAR-α) 的内源性激动剂,PPAR-α 是炎症和疼痛的关键调节因子。 NAAA-IN-3 的潜在作用是作为炎症和疼痛的治疗剂。 | |||
T81120 | PPAR | ||
SP4f为PPAR-γ激活剂,其在HK-2细胞中EC50值为826 nM。在瑞士白化病小鼠中,SP4f能够降低血糖和脂质过氧化水平,同时提升谷胱甘肽含量和过氧化氢酶活性。 | |||
T27228 | |||
E-3030 free acid is a peroxisome proliferator-activated receptor (PPAR) agonist. E-3030 decreased blood glucose, triglyceride, non-esterified fatty acids, and insulin levels and increased blood adiponectin levels. Triglyceride- and non-high-density lipopr | |||
T37579 | |||
Highly selective orally active peroxisome proliferator-activated receptor (PPAR)γ agonist (pEC50 values are 8.05, < 4 and < 4 for human PPARγ, PPARα and PPARδ receptors respectively). Decreases glucose, fatty acid and triglyceride levels following oral administration in vivo. Brown et al (1999) A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48 1415 PMID:10389847 |Nugent et al (2001) Potentiation of glucose uptake in 3T3-L1 adipocytes by PPARγ agonists is maintained in cells expressing a PPARγ dominant-negative mutant: evidence for selectivity in the downstream responses to PPARγ activation. Mol.Endocrinol. 15 1729 PMID:11579205 |Way et al (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists. J.Biol.Chem. 276 25651 PMID:11373275 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02575 | PPAR gamma/PPARG Protein, Human, Recombinant (His & GST) | Human | Baculovirus Insect Cells | ||
Peroxisome proliferator-activated receptor gamma (PPARG), a nuclear hormone receptor, plays a critical role in the lipid and glucose homeostasis, adipocyte differentiation, as well as intracellular insulin-signaling events. The peroxisome proliferator-activated receptor gamma (PPARgamma) regulates osteoblast and osteoclast differentiation, and is the molecular target of thiazolidinediones (TZDs), insulin sensitizers that enhance glucose utilization and adipocyte differentiation. Peroxisome proliferator-activated receptor gamma (PPARG) is a transcription factor involved in atherosclerosis and related diseases. Peroxisome proliferator-activated receptor gamma (PPARG) plays an important role in the pathogenesis and maintenance of essential hypertension (EH).The functional single nucleotide polymorphisms in peroxisome proliferator-activated receptor gamma (PPARG) gene were predicted to be correlated with the susceptibility of colorectal cancer (CRC).
|
|||||
TMPY-06837 | PPAR alpha/PPARA Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
PPAR alpha/PPARA Protein, Mouse, Recombinant (His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 31.49 kDa and the accession number is P23204.
|
|||||
TMPY-06830 | PPAR alpha/PPARA Protein, Human, Recombinant (His) | Human | E. coli | ||
PPAR alpha/PPARA Protein, Human, Recombinant (His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 31.36 kDa and the accession number is Q07869.
|
|||||
TMPH-02827 | PPAR gamma Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
PPAR gamma Protein, Mouse, Recombinant (His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 63.3 kDa and the accession number is P37238.
|
|||||
TMPH-03711 | PPAR gamma Protein, Xenopus laevis, Recombinant (His) | Xenopus laevis | E. coli | ||
Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. May play a role in the regulation of circadian rhythm.
|
|||||
TMPH-02855 | PML Protein, Mouse, Recombinant (His & Myc) | Mouse | E. coli | ||
Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Positively regulates p53/TP53 by acting at different levels (by promoting its acetylation and phosphorylation and by inhibiting its MDM2-dependent degradation). Regulates phosphorylation of ITPR3 and plays a role in the regulation of calcium homeostasis at the endoplasmic reticulum. Regulates RB1 phosphorylation and activity. Acts as both a negative regulator of PPARGC1A acetylation and a potent activator of PPAR signaling and fatty acid oxidation. Regulates translation of HIF1A by sequestering MTOR, and thereby plays a role in neoangiogenesis and tumor vascularization. Regulates PER2 nuclear localization and circadian function. Cytoplasmic PML is involved in the regulation of the TGF-beta signaling pathway. Required for normal development of the brain cortex during embryogenesis. Plays a role in granulopoiesis or monopoiesis of myeloid progenitor cells. May play a role regulating stem and progenitor cell fate in tissues as diverse as blood, brain and breast. Shows antiviral activity towards lymphocytic choriomeningitis virus (LCMV) and the vesicular stomatitis virus (VSV).
|